Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo.

Ruzek MC, Waire JS, Hopkins D, Lacorcia G, Sullivan J, Roberts BL, Richards SM, Nahill SR, Williams JM, Scaria A, Dzuris J, Shankara S, Garman RD.

Blood. 2008 Feb 1;111(3):1726-34. Epub 2007 Nov 19.

3.

ATG-induced expression of FOXP3 in human CD4(+) T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells.

Broady R, Yu J, Levings MK.

Blood. 2009 Dec 3;114(24):5003-6. doi: 10.1182/blood-2009-04-214437. Epub 2009 Oct 12.

4.

Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).

Cao T, Soto A, Zhou W, Wang W, Eck S, Walker M, Harriman G, Li L.

Cell Immunol. 2009;258(1):65-71. doi: 10.1016/j.cellimm.2009.03.013. Epub 2009 May 1.

PMID:
19410243
5.

Transforming growth factor-beta1-induced CD4+CD25+ regulatory T cells in vitro reverse and prevent a murine lupus-like syndrome of chronic graft-versus-host disease.

Su H, Ye DQ, Wang BL, Fang XH, Chen J, Wang Q, Li WX, Zhang N.

Br J Dermatol. 2008 Jun;158(6):1197-209. doi: 10.1111/j.1365-2133.2008.08555.x. Epub 2008 Apr 10.

PMID:
18410422
6.

Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.

Kang N, Tang L, Li X, Wu D, Li W, Chen X, Cui L, Ba D, He W.

Immunol Lett. 2009 Aug 15;125(2):105-13. doi: 10.1016/j.imlet.2009.06.005. Epub 2009 Jun 17.

PMID:
19539651
7.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

8.
9.

Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.

Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I.

Bone Marrow Transplant. 2007 May;39(9):537-45. Epub 2007 Mar 12.

PMID:
17351648
10.

Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD.

Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, Huehn J, Ganser A, Förster R, Prinz I.

Eur J Immunol. 2009 Nov;39(11):3091-6. doi: 10.1002/eji.200939432.

11.

Murine antithymocyte globulin T-cell depletion is mediated predominantly by macrophages, but the Fas/FasL pathway selectively targets regulatory T cells.

Neff KS, Richards SM, Williams JM, Garman RD, Ruzek MC.

Transplantation. 2011 Sep 15;92(5):523-8. doi: 10.1097/TP.0b013e31822923f7.

PMID:
21804441
12.

Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.

Hasegawa H, Inoue A, Kohno M, Lei J, Miyazaki T, Yoshie O, Nose M, Yasukawa M.

Gene Ther. 2008 Feb;15(3):171-82. Epub 2007 Nov 8.

PMID:
17989707
13.

Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS.

Blood. 2007 Mar 1;109(5):2225-33. Epub 2006 Oct 26.

14.

CCR6 regulates the function of alloreactive and regulatory CD4+ T cells during acute graft-versus-host disease.

Varona R, Cadenas V, Lozano M, Moreno-Ortiz MC, Kremer L, Martínez-A C, Márquez G.

Leuk Lymphoma. 2006 Aug;47(8):1469-76.

PMID:
16966255
15.

Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion.

LaCorcia G, Swistak M, Lawendowski C, Duan S, Weeden T, Nahill S, Williams JM, Dzuris JL.

Transplantation. 2009 Apr 15;87(7):966-74. doi: 10.1097/TP.0b013e31819c84b8.

PMID:
19352114
16.

Interferon-gamma conditioning ex vivo generates CD25+CD62L+Foxp3+ regulatory T cells that prevent allograft rejection: potential avenues for cellular therapy.

Feng G, Wood KJ, Bushell A.

Transplantation. 2008 Aug 27;86(4):578-89. doi: 10.1097/TP.0b013e3181806a60.

PMID:
18724229
17.

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Pillai AB, George TI, Dutt S, Strober S.

Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.

18.

Superagonist CD28 antibody preferentially expanded Foxp3-expressing nTreg cells and prevented graft-versus-host diseases.

Kitazawa Y, Fujino M, Li XK, Xie L, Ichimaru N, Okumi M, Nonomura N, Tsujimura A, Isaka Y, Kimura H, Hünig T, Takahara S.

Cell Transplant. 2009;18(5):627-37.

PMID:
19775525
19.

IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells.

Brandenburg S, Takahashi T, de la Rosa M, Janke M, Karsten G, Muzzulini T, Orinska Z, Bulfone-Paus S, Scheffold A.

Eur J Immunol. 2008 Jun;38(6):1643-53. doi: 10.1002/eji.200737791.

20.

Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts.

Xia G, He J, Leventhal JR.

Am J Transplant. 2008 Feb;8(2):298-306. doi: 10.1111/j.1600-6143.2007.02088.x. Epub 2008 Jan 7.

Supplemental Content

Support Center